Anzeige
Mehr »
Donnerstag, 11.09.2025 - Börsentäglich über 12.000 News
Diese Aktie sichert sich Exklusiv-Partnerschaft mit Babcock für Ukraine-Defence - Neubewertung voraus?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JH3B | ISIN: SE0003815604 | Ticker-Symbol: P0F
Frankfurt
10.09.25 | 16:43
0,439 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
EGETIS THERAPEUTICS AB Chart 1 Jahr
5-Tage-Chart
EGETIS THERAPEUTICS AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,4320,48517:39

Aktuelle News zur EGETIS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
EGETIS THERAPEUTICS Aktie jetzt für 0€ handeln
21.08.Egetis Therapeutics: Aktie steigt nach Q2-Zahlen trotz verfehlter Umsatzprognose1
21.08.Egetis Therapeutics AB: Interim report Q2 202572Egetis reports progress towards US NDA submission for tiratricol· FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis...
► Artikel lesen
18.08.Egetis Therapeutics AB: Egetis reports progress towards US NDA submission for tiratricol334FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis of the survival data set from the international real-world cohort study by...
► Artikel lesen
15.07.Egetis Therapeutics AB: Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency194Stockholm, Sweden, July 15, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
► Artikel lesen
05.05.Egetis Therapeutics AB: Egetis Confirms Launch of Emcitate in Germany369For investors and media only Stockholm, Sweden, May 5, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), a pharmaceutical company dedicated to developing therapies...
► Artikel lesen
30.04.Egetis Therapeutics AB: Interim report Q1 202585Egetis plans to launch Emcitate® in the first country, Germany, on May 1, 2025The European Commission approved Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency.In...
► Artikel lesen
26.02.Egetis Therapeutics AB: Year-End Report January-December 2024258European Commission has approved Egetis' Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency· Egetis expects to launch Emcitate in the first country, Germany...
► Artikel lesen
13.02.Egetis Therapeutics AB: European Commission approves Egetis' Emcitate (tiratricol) as the first and only treatment for patients with MCT8 deficiency276Stockholm, Sweden, February 13, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the European Commission (EC) has approved Emcitate® (tiratricol)...
► Artikel lesen
08.11.24Egetis Therapeutics AB: Interim report Q3 2024186Egetis successfully carried out directed share issuances amounting to SEK 300 million· The Company's MAA review for tiratricol (Emcitate®) at the EMA remains on track according to EMA's stipulated...
► Artikel lesen
9 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1